17a-ethinylestradiol-3-O-sulfate conjugate, 251
Absorption, 51, 134
Acne vulgaris, 175
ACTH, 107
Alcoholic steatosis, 67
Amlodipine, 60
AMP-activated protein kinase, 94
AMPK, 55, 93
Analytical, 56, 59, 62, 78, 114, 136, 137, 140, 162, 172, 175, 178, 181, 226, 240
Antiacne, 175
Antiallergic activity, 87, 88
Antidiabetic, 244
Anti-inflammation, 166
Antimicrobial, 186
Antioxidant, 170
Apoptosis, 98
Bergamottin, 90
Bioavailability, 74, 79, 80, 144, 145, 147, 162, 164, 228, 239, 252
Biomaterial, 146
Borassus flabellifer, 244
Caffeic acid, 197
Caffeine, 107
Calcium availability, 178
Carbamazepine, 148
Caspase 3, 190
Catechol, 115
Cephradine, 238
Chemoprevention, 214
Chinese medicinal formula, 78
Chitosan, 173
Cholangiocarcinoma, 109, 126, 187
Circadian rhythm, 155
Cissus quadrangularis, 170
Clearance prediction, 102, 148, 224, 245
CNS, 127
Colonic drug delivery, 173
Compound action potential, 205
Conjugation reactions and enzymes, 50, 53, 111, 119, 150, 151, 152, 154, 198
Corticosteroe, 107
COX-2, 89
Curcuma comosa, 151, 158
Curcumin, 109
Cyclophosphamide, 118
CYP2C19, 85
CYP2E1, 67
Cytochrome P450, 50, 53, 64, 65, 66, 67, 68, 69, 70, 73,74, 80, 82, 84, 100, 102, 112, 115, 137, 150, 154, 155, 157, 158, 159, 161, 163, 164, 191, 192, 194, 197, 198, 203, 220, 231, 208, 241, 243
Cytotoxicity, 173, 212
Dermopharmacokinetics, 141
Diabetic neuropathy, 190
Diagnostics, 233
Differences in metabolism (species, gender, age, diseases), 70, 71, 121, 123, 220, 228
Disposition, 49, 72, 79, 80, 127, 130, 221, 224, 243, 250, 252, 257
Drug discovery and development, 56, 75, 76, 77, 78, 79, 108, 111, 114, 127, 130, 137, 161, 167, 168, 169, 170, 171, 173, 174, 184, 185, 188, 189, 190, 202, 213, 226, 228
Drug interaction, 49, 51, 63, 68, 73, 74, 82, 84, 102, 130, 132, 158, 164, 165, 191, 192, 194, 245, 255
Drug resistance, 105
Drug uptake, 173
Dry media reaction, 183
ECV304 cells, 170
eNOS, 94
Enteric, 183
Environmental pollution, 118
Enzyme induction, 81, 82, 100, 102, 162, 194, 196, 201
Enzyme inhibition/inactivation, 52, 63, 82, 152, 157, 191, 192, 194, 197, 198, 203, 224
Enzyme kinetics, 85
Epilepsy, 148
Esterification, 183
Extrahepatic metabolism, 52, 63, 111, 152, 154
Faropenem, 61
FAS, 93
Flavin-containing monooxygenase, 121
Free fatty acid, 55
Functional interaction, 150
Gallic acid, 177
Gastric ulcer, 181
Gene expression and regulation, 55, 58, 65, 82, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 106, 152, 157, 199, 200, 235
Genomics/metabonomics/proteomics, 229
Genotoxicity, 170
Ginsenoside Rb1, 58, 71
Glucuronidation, 153
GST, 151
Heavy metal, 138
Helicobacter pylori, 147
Heme oxygenase-1, 58
Hepatocytes, 49, 54, 76, 82, 101, 102, 157, 194, 202, 245, 247, 251
Herbal extract, 186
High-throughput techniques, 56, 104, 114, 226
Houttuynia cordata, 87
HPLC, 60, 61, 177, 238
Hyaluronan, 92
Hydrogen peroxide, 215
Hypertension, 83
IC50, 187
ICP-MS, 138
Imatinib, 73, 74, 79, 80, 164
In silico, 65, 203, 243
In vitro kinetics, 69
In vitro techniques, 54, 59, 69, 70, 72, 78, 101, 104, 105, 108, 115, 133, 137, 141, 150, 162, 166, 172, 173, 178, 189, 191, 201, 204, 205, 213, 233, 245, 247, 250
Inhibition testing, 85
Interleukin, 166, 190
Ion mobility mass spectrometry, 116
Irbesartan, 60
IUGR, 107
Kahweol, 98
Kratom, 205
LC MS new method development, 114
Lipotoxicity, 55
Luteolin, 177
Luteolin-7-O-glucoside, 177
Mangifera indica L., 189
Mangosteen, 175
Mast cells, 87, 88
MASTIC, 147
Mechanism of herb-induced apoptosis, 108
Mechanisms of xenobiotic toxicities, 118
Mechanisms of xenobiotic toxicities, 54, 97, 99, 106, 109, 112, 198, 200, 206, 208, 209, 210, 211, 213, 214, 216, 217, 218
Meridine guide drug, 165
Metabolic profiling, 53, 54, 56, 113, 115, 116, 117, 154, 161, 198, 207, 220, 221
Metabolism, 50, 52, 53, 61, 63, 65, 69, 70, 72, 114, 115, 117, 150, 154, 162, 192, 207, 220, 221, 227, 228, 232
Metalloproteinases, 91
Metastasis, 96
Metformin, 95
Methicillin-resistant Staphylococcus
Microcapsules, 173
Mitragyna speciosa, 205
Mitragynine, 205
MMP-9, 90, 96
Monolithic column, 60
Mulberry, 166
Multifunctional drug delivery, 146
N-acetylglucosamine, 91, 92
Nanoemulsion, 186
Nanoparticle, 75
New LC MS quantitation method, 226
NF-kB, 90, 95
Nitric oxide, 190
Non-P450 phase I enzymes, 117, 121, 228
NQOR, 151
On-line solid-phase extraction, 61
Ovary, 118
Palm fruit fiber, 244
Pentagalloylglucopyranose, 189
PF2D, 101
P-glycoprotein, 95
Pharmacogenetics, 64, 65, 122, 123, 126, 163, 229, 230, 231, 232, 233, 236, 241, 243, 252, 257
Pharmacogenomic propranolol UGT1A, 236
Pharmacokinetic study, 61
Pharmacokinetics and Pharmacodynamics, 49, 51, 72, 78, 104, 105, 123, 127, 128, 129, 130, 131, 145, 172, 192, 219, 220, 226, 238, 232, 239, 240, 241, 242, 243, 245, 252
Phase II drug-metabolizing enzymes, 151
Photoaging, 91
Phyllanthus amarus, 84
Placenta, 111
Placental drug transport, 104
Plasma, 60
Platycodon grandiflorum, 88, 93
Platycodon radix, 67
Polymorphism, 85, 125
Population pharmacokinetic models, 148
Positron emission tomography, 145
Primordial germ cell, 118
Prodrug artifact Prasaplai, 176
Prunella vulgaris, 96
Puerarin, 94
Quality control, 59
Quercetin, 170, 215
Rat, 238
Reactive metabolites, 54, 56
Receptors/nuclear receptors, 199, 123
Redox status, 109
Resveratrol, 165
Rhizome, 138
S-allyl cysteine, 55
Sciatic nerve, 205
Self-microemulsifying drug delivery system (SMEDDS), 147
Shellac, 183
SJS/TEN, 124
Sonneratia caseolaris L., 177
SPE, 60
StAR, 107
STAT3, 98
Substrate selectivity, 153
SULT, 151
Target, 165
TBBPA, 89
Tea polyphenols, 242
Tetrahydrocannabinols, 50
Thai medicinal plants, 135, 187
Thais, 126
Tissue growth factor beta-1, 190
TJ disruption, 215
Tocotrienol, 190
Transporters, 51, 72, 73, 77, 80, 104, 111, 122, 123, 130, 132, 133, 134, 135, 145, 234, 235, 246, 247, 250, 251, 252, 254, 255, 257, 260
Tumor necrosis factor-alpha, 190
UDP-glucuronosyltransferase, 125, 153
UDPGT, 151
Ultraviolet, 91
Uniform design, 172
UVB, 92
Volatile oil, 186
Ya-hom, 181
Zingiberaceae, 138